HOME > MARKETS > MARKET COMMENTARY
  MARKET COMMENTARY
EQUITY
Lupin trades higher on receiving U.S. FDA's approval for Lenalidomide Capsules
Sep-18-2025

Lupin is currently trading at Rs. 2049.00, up by 17.85 points or 0.88% from its previous closing of Rs. 2031.15 on the BSE.

The scrip opened at Rs. 2054.75 and has touched a high and low of Rs. 2054.75 and Rs. 2023.10 respectively. So far 5323 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 2063.60 and Rs. 2013.00 respectively. The current market cap of the company is Rs. 93365.19 crore.

The promoters holding in the company stood at 46.90%, while Institutions and Non-Institutions held 46.81% and 6.28% respectively.

Lupin has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Lenalidomide Capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg. Lenalidomide Capsules are bioequivalent to Revlimid Capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg, of Bristol-Myers Squibb Company. This product will be manufactured at company’s Pithampur facility in India.

Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma (MM), in combination with dexamethasone; MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT); Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. Lenalidomide Capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg (RLD Revlimid) had estimated annual sales of $7,511 million in the U.S. (IQVIA MAT July 2025).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

  RELATED NEWS >>